{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:19:23Z","timestamp":1766269163876},"reference-count":13,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2023,4,1]]},"DOI":"10.1248\/bpb.b22-00830","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T22:15:02Z","timestamp":1680300902000},"page":"621-629","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Immunochemical Reactions of Infliximab Innovator and Biosimilars on an Infliximab Detection Kit Used for Therapeutic Drug Monitoring"],"prefix":"10.1248","volume":"46","author":[{"given":"Hiroko","family":"Shibata","sequence":"first","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[{"name":"Division of Biological Chemistry and Biologicals, National Institute of Health Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. <i>Expert Rev. Clin. Immunol.<\/i>, <b>15<\/b>, 837\u2013848 (2019).","DOI":"10.1080\/1744666X.2019.1630273"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. <i>Frontline Gastroenterol.<\/i>, <b>7<\/b>, 289\u2013300 (2016).","DOI":"10.1136\/flgastro-2016-100685"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, Wagner C, Han J, Westhovens R. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. <i>Ann. Rheum. Dis.<\/i>, <b>66<\/b>, 1233\u20131238 (2007).","DOI":"10.1136\/ard.2006.065995"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) St.Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis Rheum.<\/i>, <b>46<\/b>, 1451\u20131459 (2002).","DOI":"10.1002\/art.10302"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. <i>Mod. Rheumatol.<\/i>, <b>19<\/b>, 478\u2013487 (2009).","DOI":"10.1007\/s10165-009-0195-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nakae K, Masui S, Yonezawa A, <i>et al.<\/i> Potential application of measuring serum infliximab levels in rheumatoid arthritis management: a retrospective study based on KURAMA cohort data. <i>PLOS ONE<\/i>, <b>16<\/b>, e0258601 (2021).","DOI":"10.1371\/journal.pone.0258601"},{"key":"7","unstructured":"7) LSI Medience Corporation. \u201cRemi-check Q [package insert].\u201d (2016)."},{"key":"8","unstructured":"8) Hirayama Y, Takeuchi T. Biological product treatment in rheumatoid arthritis: usefulness of detection method of serum level in infliximab drug therapy. <i>Mod. Med.<\/i>, <b>64<\/b>, 285\u2013289 (2018)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Feagan BG, Lam G, Ma C, Lichtenstein GR. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. <i>Aliment. Pharmacol. Ther.<\/i>, <b>49<\/b>, 31\u201340 (2019).","DOI":"10.1111\/apt.14997"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Inagaki T, Isesaki T, Kawana K, Funakoshi R. Viability of a serum infliximab concentration-detecting reagent as a qualitative assay for an infliximab biosimilar. <i>Biol. Pharm. Bull.<\/i>, <b>44<\/b>, 1272\u20131279 (2021).","DOI":"10.1248\/bpb.b21-00145"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Neveu B, Kunst A, Prosser C, Robitaille R. An <i>in vitro<\/i> comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels. <i>Clin. Biochem.<\/i>, <b>78<\/b>, 58\u201362 (2020).","DOI":"10.1016\/j.clinbiochem.2020.01.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Lee C, Jeong M, Lee JAJ, Seo S, Cho SC, Zhang W, Jaquez O. Glycosylation profile and biological activity of Remicade<sup>\u00ae<\/sup> compared with Flixabi<sup>\u00ae<\/sup> and Remsima<sup>\u00ae<\/sup>. <i>MAbs<\/i>, <b>9<\/b>, 968\u2013977 (2017).","DOI":"10.1080\/19420862.2017.1337620"},{"key":"13","unstructured":"13) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. \u201cICH M10 Guidline Step 4.\u201d: \u2039https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf\u203a. accessed 3 March, 2023."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/4\/46_b22-00830\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T03:32:14Z","timestamp":1680319934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/4\/46_b22-00830\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00830","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"article-number":"b22-00830"}}